Weekly Recap: SLS009 Phase 2 enrollment and REGAL 78 of 80 events
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is advancing SLS009 in a Phase 2 AML trial with 28 of 80 patients enrolled and topline data due Q4 2026, while its blinded, event—driven REGAL study reports 78 of 80 deaths and no confirmed final analysis; shares slipped after pancreatic organoid data a…